A leading RNAi therapeutics company.

Cubist will need the lead in advancing ALN-RSV02 in the pediatric setting in continuing collaboration and 50-50 financing with Alnylam, and Cubist retains an opt-in correct for ALN-RSV01 in the adult transplant indication.. Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today that it offers initiated a Stage IIb announced trial in adult lung transplant sufferers with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus infection.Top-line email address details are expected by the next quarter of 2010. Named AeroTrial, the study enrolled approximately 540 sufferers at 75 sites in the usa and Europe. In the double-blind, randomized, placebo-controlled, dose-ranging trial, patients with moderate to severe asthma who had been inadequately managed on the mix of inhaled corticosteroids and long-performing beta agonists had been assigned to receive among three Aerovant dosages or placebo by inhalation twice daily for 12 weeks. In this right time the standard ICS and LABA therapies had been withdrawn gradually. The trial’s major endpoint may be the incidence of asthma exacerbations on Aerovant therapy in comparison with placebo. Secondary endpoints include pulmonary function, period to exacerbation, daily peak expiratory flow and symptom ratings, immunoglobulin E amounts and fractional concentration of expired nitric oxide .